Health and Healthcare
Abbott (ABT) Stent Slowdown, Bad For Johnson & Johnson (JNJ) And Boston Scientific (BSX)
Published:
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says it expects to "take a 25-30% market share in 2008." But, of course, it looks like they miscalculated by employing all of those people in the first place.
No matter how wrong-headed that Abbott seems, it is bad news for the two incumbents in the stent business, Johnson & Johnson (JNJ) and Boston Scientific (BSX). BSX is already struggling with falling operating income and a tremendous debt load.
Douglas A. McIntyre
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
